US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

UpStream Bio Inc.

7.80

+0.44005.98%

Post-market: 7.800.00000.00%16:21 EST

Volume:1.15M

Turnover:8.84M

Market Cap:421.50M

PE:-3.43

High:8.01

Open:7.37

Low:7.33

Close:7.36

52wk High:33.68

52wk Low:5.14

Shares:54.04M

Float Shares:31.42M

Volume Ratio:0.87

T/O Rate:3.67%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2740

EPS(LYR):-5.5835

ROE:-40.80%

ROA:-28.15%

PB:1.11

PE(LYR):-1.40

Loading ...

Overview Company News Filings

Upstream Bio Inc - Over 90% of Patients Transitioned to Phase 2 Valour Study

THOMSON REUTERS

Upstream Bio Reports Positive Top-Line Results From the Phase 2 Valiant Trial of Verekitug for the Treatment of Severe Asthma

THOMSON REUTERS

Upstream Bio Announces Top-Line Results from Phase 2 VALIANT Trial of Verekitug in Severe Asthma

Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB) and BioNano Genomics (BNGO)

Upstream Bio Showcases Verekitug’s Promise in Severe Respiratory Disease Trials

Upstream Bio CEO to Present at J.P. Morgan Healthcare Conference

Upstream Bio (UPB): Reassessing Valuation After NASDAQ Biotechnology Index Inclusion and Sharp 3‑Month Rally

Simply Wall St.

Does Mizuho’s New Coverage of Upstream Bio (UPB) Reframe the Stock’s Risk‑Reward Narrative?

Simply Wall St.

Upstream Bio Inc : Mizuho Initiates Coverage With Outperform Rating; Price Target $51

THOMSON REUTERS

Upstream Bio Initiated at Outperform by LifeSci Capital

Promising Outlook for Upstream Bio, Inc. Driven by Verekitug’s Clinical Advancements

Upstream Bio Initiated at Outperform by Evercore ISI Group

Upstream Bio initiated with an Outperform at Evercore ISI

Upstream Bio, Inc.’s Verekitug: A Promising Buy with Blockbuster Potential in Asthma and COPD Markets

Upstream Bio, Inc. Receives Buy Rating Due to Promising Clinical Trial Results and Strong Drug Pipeline

Upstream Bio Inc Files for Mixed Shelf ; Size Not Disclosed - SEC Filing

THOMSON REUTERS

Upstream Bio reports Q3 net loss of $33.7 million on higher R&D expenses

Upstream Bio (UPB): Evaluating Valuation After NORGES BANK’s Strategic Stake Boost

Simply Wall St.

Upstream Bio Inc. to Participate in Stifel Healthcare Conference

Upstream Bio’s Promising Trials and Strategic Outlook Drive Buy Rating

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/UPB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"UPB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UPB\",,,,,undefined,":{"symbol":"UPB","market":"US","secType":"STK","nameCN":"UpStream Bio Inc.","latestPrice":7.8,"timestamp":1772658000000,"preClose":7.36,"halted":0,"volume":1152331,"hourTrading":{"tag":"盘后","latestPrice":7.8,"preClose":7.8,"latestTime":"16:21 EST","volume":9569,"amount":74629.63574499999,"timestamp":1772659308006,"change":0,"changeRate":0,"amplitude":0.019231},"delay":0,"changeRate":0.059782608695652106,"floatShares":31417476,"shares":54038591,"eps":-2.274,"marketStatus":"Post-Mkt","change":0.44,"latestTime":"03-04 16:40:40 EST","open":7.37,"high":8.01,"low":7.333,"amount":8841734.796817,"amplitude":0.091984,"askPrice":8.33,"askSize":1,"bidPrice":7.3,"bidSize":3,"shortable":3,"etf":0,"ttmEps":-2.274,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772672400000},"marketStatusCode":4,"adr":0,"listingDate":1728619200000,"exchange":"NASDAQ","adjPreClose":7.36,"preHourTrading":{"tag":"盘前","latestPrice":7.57,"preClose":7.36,"latestTime":"08:58 EST","volume":1031,"amount":7692.6360757,"timestamp":1772632712794,"change":0.21,"changeRate":0.028533,"amplitude":0.019022},"postHourTrading":{"tag":"盘后","latestPrice":7.8,"preClose":7.8,"latestTime":"16:21 EST","volume":9569,"amount":74629.63574499999,"timestamp":1772659308006,"change":0,"changeRate":0,"amplitude":0.019231},"volumeRatio":0.874052,"impliedVol":0.62,"impliedVolPercentile":0.2706},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UPB\",,,,,undefined,":{"symbol":"UPB","floatShares":31417476,"roa":"-28.15%","roe":"-40.80%","lyrEps":-5.58348,"volumeRatio":0.874052,"shares":54038591,"dividePrice":0,"high":8.01,"amplitude":0.091984,"preClose":7.36,"low":7.333,"week52Low":5.14,"pbRate":"1.11","psRate":"150.59","week52High":33.68,"institutionHeld":0,"latestPrice":7.8,"committee":0.5,"eps":-2.274,"divideRate":0,"volume":1152331,"delay":0,"ttmEps":-2.274,"open":7.37,"prevYearClose":27.15,"prevWeekClose":7.68,"prevMonthClose":7.68,"prevQuarterClose":27.15,"fiveDayClose":7.74,"twentyDayClose":30.79,"sixtyDayClose":27.74},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/UPB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-06","symbol":"UPB","fiscalQuarterEnding":"2025/03","expectedEps":-0.49,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746504000000,"reportTimeType":"pre","actualEps":-0.51},{"market":"US","date":"2025-03-12","symbol":"UPB","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741752000000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"UPB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"UPB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.875,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.875,"analysts":8,"updateTime":1766034000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/UPB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"UPB","date":"2026-03-03","current":-3.236588,"percent":0.99711,"low":-36.237602,"twenty":-13.734024,"median":-9.763246,"eighty":-7.392881,"high":-3.395484,"avg":-11.837926,"sd":6.762623,"marketCap":416097150},"quantilePoints":[{"date":"2024-10-11","current":-21.547111,"twenty":-21.096119,"median":-20.419631,"eighty":-19.743142,"marketCap":872808815},{"date":"2024-10-18","current":-29.91246,"twenty":-29.856691,"median":-29.151973,"eighty":-22.814588,"marketCap":1211664002},{"date":"2024-10-25","current":-33.154958,"twenty":-33.128498,"median":-29.931472,"eighty":-28.137991,"marketCap":1343007876},{"date":"2024-10-31","current":-32.943274,"twenty":-33.154958,"median":-32.429578,"eighty":-29.151973,"marketCap":1334433205},{"date":"2024-11-08","current":-35.748083,"twenty":-33.28726,"median":-32.943274,"eighty":-29.633615,"marketCap":1448047598},{"date":"2024-11-15","current":-26.036965,"twenty":-33.27403,"median":-32.40745,"eighty":-26.47861,"marketCap":1390295829},{"date":"2024-11-22","current":-17.866537,"twenty":-33.154958,"median":-29.91246,"eighty":-25.555171,"marketCap":954019497},{"date":"2024-11-29","current":-21.951751,"twenty":-33.154958,"median":-29.151973,"eighty":-21.870823,"marketCap":1172157663},{"date":"2024-12-06","current":-22.082237,"twenty":-33.144374,"median":-26.689395,"eighty":-21.903572,"marketCap":1179125222},{"date":"2024-12-13","current":-20.486294,"twenty":-33.088806,"median":-26.036965,"eighty":-21.589777,"marketCap":1093906626},{"date":"2024-12-20","current":-16.672089,"twenty":-32.969734,"median":-24.742143,"eighty":-20.201232,"marketCap":890239542},{"date":"2024-12-27","current":-19.517686,"twenty":-32.858694,"median":-23.382078,"eighty":-19.472518,"marketCap":1042185906},{"date":"2025-01-03","current":-16.36093,"twenty":-32.784605,"median":-22.553994,"eighty":-19.153329,"marketCap":873624596},{"date":"2025-01-10","current":-16.250519,"twenty":-32.617811,"median":-22.077219,"eighty":-18.486847,"marketCap":867728970},{"date":"2025-01-17","current":-10.92067,"twenty":-31.635576,"median":-21.951751,"eighty":-17.320504,"marketCap":583131018},{"date":"2025-01-24","current":-10.810259,"twenty":-29.950484,"median":-21.600443,"eighty":-16.501454,"marketCap":577235392},{"date":"2025-01-31","current":-11.041119,"twenty":-29.91246,"median":-20.852659,"eighty":-16.230444,"marketCap":589562611},{"date":"2025-02-07","current":-8.561886,"twenty":-29.633615,"median":-19.703378,"eighty":-11.472726,"marketCap":457179006},{"date":"2025-02-14","current":-7.3574,"twenty":-29.151973,"median":-19.472518,"eighty":-10.92067,"marketCap":392863085},{"date":"2025-02-21","current":-8.260764,"twenty":-28.137991,"median":-19.276941,"eighty":-10.810259,"marketCap":441100026},{"date":"2025-02-28","current":-7.839194,"twenty":-27.097043,"median":-19.030874,"eighty":-9.965112,"marketCap":418589453},{"date":"2025-03-07","current":-8.451474,"twenty":-26.562924,"median":-18.338294,"eighty":-8.834903,"marketCap":451283380},{"date":"2025-03-14","current":-7.737899,"twenty":-26.318012,"median":-17.866537,"eighty":-8.491624,"marketCap":485986508},{"date":"2025-03-21","current":-6.875286,"twenty":-26.085144,"median":-16.857781,"eighty":-8.411325,"marketCap":431809204},{"date":"2025-03-28","current":-5.816236,"twenty":-26.012875,"median":-16.36093,"eighty":-8.168077,"marketCap":365294494},{"date":"2025-04-04","current":-5.380659,"twenty":-25.645507,"median":-16.240482,"eighty":-7.936302,"marketCap":337937638},{"date":"2025-04-11","current":-5.466066,"twenty":-24.254326,"median":-13.751211,"eighty":-7.734483,"marketCap":343301728},{"date":"2025-04-17","current":-7.191293,"twenty":-23.886958,"median":-11.472726,"eighty":-7.5722,"marketCap":451656335},{"date":"2025-04-25","current":-7.652492,"twenty":-23.286723,"median":-11.041119,"eighty":-7.514132,"marketCap":480622419},{"date":"2025-05-02","current":-7.693506,"twenty":-22.857123,"median":-10.850408,"eighty":-7.502769,"marketCap":483198327},{"date":"2025-05-09","current":-6.005612,"twenty":-22.499792,"median":-10.810259,"eighty":-7.378434,"marketCap":475536334},{"date":"2025-05-16","current":-5.964849,"twenty":-22.162536,"median":-10.288315,"eighty":-7.189481,"marketCap":472308712},{"date":"2025-05-23","current":-6.324914,"twenty":-22.076215,"median":-9.921951,"eighty":-6.77963,"marketCap":500819374},{"date":"2025-05-30","current":-6.352089,"twenty":-22.02402,"median":-9.013568,"eighty":-6.524152,"marketCap":502971123},{"date":"2025-06-06","current":-7.357554,"twenty":-21.951751,"median":-8.668839,"eighty":-6.524152,"marketCap":582585803},{"date":"2025-06-13","current":-7.853492,"twenty":-21.855392,"median":-8.531773,"eighty":-6.551855,"marketCap":621855206},{"date":"2025-06-20","current":-7.228474,"twenty":-21.688772,"median":-8.441437,"eighty":-6.588317,"marketCap":572364999},{"date":"2025-06-27","current":-7.432284,"twenty":-21.589777,"median":-8.421362,"eighty":-6.683973,"marketCap":588503110},{"date":"2025-07-03","current":-7.60892,"twenty":-21.547111,"median":-8.293047,"eighty":-6.875286,"marketCap":602489473},{"date":"2025-07-11","current":-8.043715,"twenty":-21.219023,"median":-8.229183,"eighty":-7.004282,"marketCap":636917443},{"date":"2025-07-18","current":-7.500221,"twenty":-20.486294,"median":-8.00983,"eighty":-7.116503,"marketCap":593882481},{"date":"2025-07-25","current":-9.06956,"twenty":-20.325696,"median":-7.964314,"eighty":-7.165671,"marketCap":718145935},{"date":"2025-08-01","current":-10.401121,"twenty":-19.703378,"median":-8.043715,"eighty":-7.186764,"marketCap":823581592},{"date":"2025-08-08","current":-8.173881,"twenty":-19.517686,"median":-8.19076,"eighty":-7.191293,"marketCap":853925323},{"date":"2025-08-15","current":-9.608438,"twenty":-19.472518,"median":-8.256445,"eighty":-7.228474,"marketCap":1003793530},{"date":"2025-08-22","current":-9.154334,"twenty":-19.472518,"median":-8.332111,"eighty":-7.228474,"marketCap":956353234},{"date":"2025-08-29","current":-8.648626,"twenty":-19.29215,"median":-8.429698,"eighty":-7.242061,"marketCap":903521996},{"date":"2025-09-05","current":-10.155428,"twenty":-19.267816,"median":-8.442215,"eighty":-7.274671,"marketCap":1060937523},{"date":"2025-09-12","current":-9.247219,"twenty":-19.117195,"median":-8.531282,"eighty":-7.282823,"marketCap":966056931},{"date":"2025-09-19","current":-8.911801,"twenty":-19.040911,"median":-8.561886,"eighty":-7.298422,"marketCap":931015804},{"date":"2025-09-26","current":-8.416414,"twenty":-18.814066,"median":-8.561394,"eighty":-7.303028,"marketCap":879262754},{"date":"2025-10-03","current":-9.592957,"twenty":-18.486847,"median":-8.591998,"eighty":-7.324944,"marketCap":1002176247},{"date":"2025-10-10","current":-10.212191,"twenty":-18.290115,"median":-8.630565,"eighty":-7.351996,"marketCap":1066867560},{"date":"2025-10-17","current":-11.4971,"twenty":-18.113457,"median":-8.648626,"eighty":-7.357523,"marketCap":1201102033},{"date":"2025-10-24","current":-10.903668,"twenty":-17.908694,"median":-8.694854,"eighty":-7.362988,"marketCap":1139106192},{"date":"2025-10-31","current":-13.298037,"twenty":-17.320504,"median":-8.903157,"eighty":-7.366819,"marketCap":1389245933},{"date":"2025-11-07","current":-10.460565,"twenty":-17.071577,"median":-8.919541,"eighty":-7.375835,"marketCap":1278553063},{"date":"2025-11-14","current":-10.319087,"twenty":-16.746366,"median":-8.953083,"eighty":-7.3842,"marketCap":1261260713},{"date":"2025-11-21","current":-11.035322,"twenty":-16.535581,"median":-9.042102,"eighty":-7.390371,"marketCap":1348803231},{"date":"2025-11-28","current":-12.644639,"twenty":-16.41714,"median":-9.068084,"eighty":-7.395598,"marketCap":1545503702},{"date":"2025-12-05","current":-12.264416,"twenty":-16.306728,"median":-9.154334,"eighty":-7.402392,"marketCap":1499030514},{"date":"2025-12-12","current":-12.145044,"twenty":-16.258549,"median":-9.253501,"eighty":-7.413262,"marketCap":1484440094},{"date":"2025-12-19","current":-13.201711,"twenty":-16.238474,"median":-9.412348,"eighty":-7.419454,"marketCap":1613592327},{"date":"2025-12-26","current":-13.38298,"twenty":-16.206354,"median":-9.577476,"eighty":-7.422171,"marketCap":1635748149},{"date":"2026-01-02","current":-12.003565,"twenty":-15.686418,"median":-9.608438,"eighty":-7.426849,"marketCap":1467147745},{"date":"2026-01-09","current":-12.175992,"twenty":-13.691713,"median":-9.623919,"eighty":-7.437719,"marketCap":1488222796},{"date":"2026-01-16","current":-13.661516,"twenty":-14.223893,"median":-9.706483,"eighty":-7.459459,"marketCap":1669792461},{"date":"2026-01-23","current":-14.055003,"twenty":-14.055003,"median":-9.763246,"eighty":-7.459459,"marketCap":1717886807},{"date":"2026-01-30","current":-13.679201,"twenty":-14.055003,"median":-9.837934,"eighty":-7.487886,"marketCap":1671954005},{"date":"2026-02-06","current":-11.495127,"twenty":-13.997527,"median":-9.967119,"eighty":-7.498759,"marketCap":1405003366},{"date":"2026-02-13","current":-5.659139,"twenty":-13.966579,"median":-10.045793,"eighty":-7.487886,"marketCap":691693964},{"date":"2026-02-20","current":-3.775707,"twenty":-13.794285,"median":-9.921951,"eighty":-7.430925,"marketCap":461489567},{"date":"2026-02-27","current":-3.49275,"twenty":-13.743121,"median":-9.768407,"eighty":-7.40375,"marketCap":426904868},{"date":"2026-03-03","current":-3.404326,"twenty":-13.734024,"median":-9.763246,"eighty":-7.392881,"marketCap":416097150}],"updateTime":1772626243399},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"UPB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610936506","title":"Upstream Bio Inc - Over 90% of Patients Transitioned to Phase 2 Valour Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2610936506","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610936506?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:00","pubTimestamp":1770807601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA2GXKFY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2610365179","title":"Upstream Bio Reports Positive Top-Line Results From the Phase 2 Valiant Trial of Verekitug for the Treatment of Severe Asthma","url":"https://stock-news.laohu8.com/highlight/detail?id=2610365179","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610365179?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:00","pubTimestamp":1770807601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA2GXKFY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2610672247","title":"Upstream Bio Announces Top-Line Results from Phase 2 VALIANT Trial of Verekitug in Severe Asthma","url":"https://stock-news.laohu8.com/highlight/detail?id=2610672247","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610672247?lang=en_us&edition=fundamental","pubTime":"2026-02-11 07:00","pubTimestamp":1770764411,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc. announced that it will report top-line results from the Phase 2 VALIANT trial of verekitug, a thymic stromal lymphopoietin  receptor antagonist in development for severe asthma, on February 11, 2026. The VALIANT trial is a global, randomized, double-blind, placebo-controlled clinical study that evaluated the safety and efficacy of verekitug in 478 patients with severe asthma. The webcast presenting the results will be accessible on the company’s website, with a replay available following the event. The results have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on February 10, 2026, and is solel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL8vYNTJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","SG9999014039.USD","SG9999014013.SGD","BK4588","LU2210150020.SGD","UPB","LU2095319765.USD","BK4139","SG9999014021.USD","IE00B64PRP62.GBP","NDAQ","LU2210149790.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2604437913","title":"Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB) and BioNano Genomics (BNGO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604437913","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604437913?lang=en_us&edition=fundamental","pubTime":"2026-01-17 02:10","pubTimestamp":1768587040,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Upstream Bio, Inc. (UPB – Research Report) and BioNa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-upstream-bio-inc-upb-and-bionano-genomics-bngo-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-upstream-bio-inc-upb-and-bionano-genomics-bngo-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4137","BNGO","BK4581","BK4121","LU0029874061.USD","UPB","BK4585","XLV","XBI","LABU","HCSG","BK4588","BK4139","BK4575"],"gpt_icon":0},{"id":"2602514234","title":"Upstream Bio Showcases Verekitug’s Promise in Severe Respiratory Disease Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514234","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514234?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:04","pubTimestamp":1768219469,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc. has released a corporate presentation detailing recent progress in its clinical-stage immunology programs focused on severe respiratory diseases. The company highlighted the completion of the Phase 2 VIBRANT trial evaluating verekitug in patients with chronic rhinosinusitis with nasal polyps . Verekitug met its primary endpoint, achieving a reduction in nasal polyp score  of -1.8 , and demonstrated key secondary benefits, including a reduction in need for surgery or steroids by 76% . The treatment was generally well tolerated, with no serious adverse events reported. Additional Phase 2 studies are underway, including VALIANT in severe asthma, with top-line results expected in Q1 2026, and VENTURE in COPD, which is currently enrolling participants. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL1db9bs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2601725885","title":"Upstream Bio CEO to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601725885","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601725885?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614415,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 2:15 p.m. PT. The company's Chief Executive Officer, Dr. Rand Sutherland, will deliver the presentation, which will be available via live webcast on the Investors section of Upstream Bio's website. A replay will also be accessible following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL34xFQl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014021.USD","LU0314104364.USD","BK4588","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","NDAQ","BK4139","LU2210150020.SGD","SG9999014039.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","UPB","LU2095319765.USD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2593941230","title":"Upstream Bio (UPB): Reassessing Valuation After NASDAQ Biotechnology Index Inclusion and Sharp 3‑Month Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2593941230","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593941230?lang=en_us&edition=fundamental","pubTime":"2025-12-23 22:15","pubTimestamp":1766499309,"startTime":"0","endTime":"0","summary":"Upstream Bio (UPB) just earned a spot in the NASDAQ Biotechnology Index, a visibility upgrade that can quietly reshape its investor base, trading volume, and how the market values its pipeline.\nSee our latest analysis for Upstream Bio.\nThat index inclusion lands on top of already strong momentum, with the share price at $30.43 and an 86.92% 3 month share price return that suggests investors are re-rating its risk and growth profile rather than just reacting to a one day move.\nIf this kind of...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/upstream-bio-upb-reassessing-valuation-after-nasdaq-biotechn","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/upstream-bio-upb-reassessing-valuation-after-nasdaq-biotechn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PSQ","SQQQ","UPB","USAW.SI","MNQmain","TQQQ","QID",".IXIC","NQmain","QLD","TSYW.SI","BK4139","NBI","NVIW.SI","USJW.SI"],"gpt_icon":1},{"id":"2592146266","title":"Does Mizuho’s New Coverage of Upstream Bio (UPB) Reframe the Stock’s Risk‑Reward Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2592146266","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592146266?lang=en_us&edition=fundamental","pubTime":"2025-12-20 21:17","pubTimestamp":1766236664,"startTime":"0","endTime":"0","summary":"Earlier this week, Mizuho Securities analyst Joseph Catanzaro initiated coverage on Upstream Bio with a buy rating, signaling fresh Wall Street attention on the biotech name.\nThis coverage launch brings Catanzaro’s recent track record, where fewer than half of his calls were successful but still generated an 8.5% average return, into focus for investors assessing the endorsement’s weight.\nNext, we’ll examine how this new Mizuho coverage and Catanzaro’s track record might influence Upstream...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/does-mizuhos-new-coverage-of-upstream-bio-upb-reframe-the-st","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/does-mizuhos-new-coverage-of-upstream-bio-upb-reframe-the-st","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["UPB","MFG","BK4207","BK4139"],"gpt_icon":0},{"id":"2592296819","title":"Upstream Bio Inc : Mizuho Initiates Coverage With Outperform Rating; Price Target $51","url":"https://stock-news.laohu8.com/highlight/detail?id=2592296819","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592296819?lang=en_us&edition=fundamental","pubTime":"2025-12-18 12:07","pubTimestamp":1766030833,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO00L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2588605370","title":"Upstream Bio Initiated at Outperform by LifeSci Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2588605370","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588605370?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:04","pubTimestamp":1764680640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/UPB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 02, 2025 08:04 ET (13:04 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2586542740","title":"Promising Outlook for Upstream Bio, Inc. Driven by Verekitug’s Clinical Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2586542740","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586542740?lang=en_us&edition=fundamental","pubTime":"2025-11-25 19:55","pubTimestamp":1764071749,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Tessa Romero has maintained their bullish stance on UPB stock, giving a Buy rating on November 18. Tessa Romero’s rating is bas...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-outlook-for-upstream-bio-inc-driven-by-verekitugs-clinical-advancements-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-outlook-for-upstream-bio-inc-driven-by-verekitugs-clinical-advancements-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0971096721.USD","BK4139","LU0106831901.USD","LU0882574139.USD","LU1720051017.SGD","UPB","BK4585","LU2023251221.USD","LU0098860793.USD","LU0006306889.USD","LU1363072403.SGD","LU2111349929.HKD","BK4588","LU1732800096.USD","LU1720051108.HKD","LU1791710400.SGD","LU1244550494.USD","LU1668664300.SGD","LU0912757837.SGD","LU0267386448.USD","LU1732799900.SGD","LU1989772840.SGD","LU2357305700.SGD","BK4127","BK4516","LU0314104364.USD","LU2133065610.SGD","IE00BKVL7J92.USD","LU1074936037.SGD","LU2089284900.SGD","BK4581","IE00BZ1G4Q59.USD","LU0158827781.USD","LU0234570918.USD","LU0557290698.USD","LU2271345857.HKD","BK4534","BK4504","LU0795875086.SGD","LU2089283258.USD","LU1244550577.SGD","LU0795875169.SGD","LU1162221912.USD","LU1244550221.USD","LU2347655156.SGD","LU0106261372.USD","LU1989772923.USD","LU0528227936.USD","LU1791710582.SGD","LU0158827948.USD"],"gpt_icon":0},{"id":"2584370937","title":"Upstream Bio Initiated at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2584370937","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584370937?lang=en_us&edition=fundamental","pubTime":"2025-11-18 20:50","pubTimestamp":1763470200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/UPB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2025 07:50 ET (12:50 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2584933652","title":"Upstream Bio initiated with an Outperform at Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2584933652","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584933652?lang=en_us&edition=fundamental","pubTime":"2025-11-18 17:55","pubTimestamp":1763459715,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Cory Kasimov initiated coverage of Upstream Bio (UPB) with an Outperform rating and $40 price target The firm says the company...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/upstream-bio-initiated-with-an-outperform-at-evercore-isi-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/upstream-bio-initiated-with-an-outperform-at-evercore-isi-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2584933569","title":"Upstream Bio, Inc.’s Verekitug: A Promising Buy with Blockbuster Potential in Asthma and COPD Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2584933569","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584933569?lang=en_us&edition=fundamental","pubTime":"2025-11-18 17:46","pubTimestamp":1763459190,"startTime":"0","endTime":"0","summary":"Upstream Bio, Inc. (UPB) has received a new Buy rating, initiated by Evercore ISI analyst, Cory Kasimov. Cory Kasimov has given his Buy rating due ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/upstream-bio-inc-s-verekitug-a-promising-buy-with-blockbuster-potential-in-asthma-and-copd-markets-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/upstream-bio-inc-s-verekitug-a-promising-buy-with-blockbuster-potential-in-asthma-and-copd-markets-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2581746637","title":"Upstream Bio, Inc. Receives Buy Rating Due to Promising Clinical Trial Results and Strong Drug Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2581746637","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581746637?lang=en_us&edition=fundamental","pubTime":"2025-11-05 23:55","pubTimestamp":1762358152,"startTime":"0","endTime":"0","summary":"William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating on October 20. Matt Phipps has given his Bu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/upstream-bio-inc-receives-buy-rating-due-to-promising-clinical-trial-results-and-strong-drug-pipeline-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/upstream-bio-inc-receives-buy-rating-due-to-promising-clinical-trial-results-and-strong-drug-pipeline-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2581172250","title":"Upstream Bio Inc Files for Mixed Shelf ; Size Not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581172250","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581172250?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:38","pubTimestamp":1762346286,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nFWN3WH0R3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2581729242","title":"Upstream Bio reports Q3 net loss of $33.7 million on higher R&D expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2581729242","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581729242?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:00","pubTimestamp":1762344048,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc. reported a net loss of $33.7 million for the third quarter ended September 30, 2025, compared to a net loss of $16.0 million for the same period in 2024. Research and development expenses were $33.0 million, up from $15.4 million, primarily due to increased clinical and manufacturing expenses for the verekitug programs. General and administrative expenses rose to $5.5 million from $4.1 million, mainly driven by higher personnel-related and professional service fees. As of September 30, 2025, the company held $372.4 million in cash, cash equivalents, and short-term investments, expected to fund operations through 2027. Key business developments included positive top-line results from the Phase 2 VIBRANT trial of verekitug in CRSwNP, ongoing enrollment in the VENTURE Phase 2 trial in COPD, and plans to report top-line results from the VALIANT Phase 2 trial in severe asthma in the first quarter of 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL1FN7TH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","BK4139","LU2095319765.USD","BK4585","BK4588","LU2210149790.SGD","BK4112","UPB","IE00BKPKM429.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2580268902","title":"Upstream Bio (UPB): Evaluating Valuation After NORGES BANK’s Strategic Stake Boost","url":"https://stock-news.laohu8.com/highlight/detail?id=2580268902","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580268902?lang=en_us&edition=fundamental","pubTime":"2025-11-03 11:16","pubTimestamp":1762139804,"startTime":"0","endTime":"0","summary":"Upstream Bio (UPB) caught investor attention after NORGES BANK acquired nearly 2 million shares, increasing its overall stake to just over 5%. The move suggests institutional interest in the company’s pipeline of therapies.\nSee our latest analysis for Upstream Bio.\nThe surge in Upstream Bio’s share price, up an impressive 38.8% over the last 30 days, mirrors renewed optimism after NORGES BANK’s stake increase and management’s high-profile conference appearances. While total shareholder return...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/upstream-bio-upb-evaluating-valuation-after-norges-banks-str","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/upstream-bio-upb-evaluating-valuation-after-norges-banks-str","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2579463895","title":"Upstream Bio Inc. to Participate in Stifel Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2579463895","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579463895?lang=en_us&edition=fundamental","pubTime":"2025-10-31 19:00","pubTimestamp":1761908417,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc., a clinical-stage company focused on treatments for inflammatory diseases, will present at the Stifel 2025 Healthcare Conference in New York on November 11, 2025, at 9:20 a.m. ET. A live webcast of the presentation will be available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on October 31, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL4f5Cv1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4127","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SF","LU0314104364.USD","BK4588","NDAQ","LU2095319765.USD","IE00BKPKM429.USD","UPB","BK4585","BK4139","LU2210150020.SGD"],"gpt_icon":0},{"id":"2579125026","title":"Upstream Bio’s Promising Trials and Strategic Outlook Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2579125026","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579125026?lang=en_us&edition=fundamental","pubTime":"2025-10-30 22:25","pubTimestamp":1761834335,"startTime":"0","endTime":"0","summary":"William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating on October 20. Matt Phipps has given his Bu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/upstream-bios-promising-trials-and-strategic-outlook-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/upstream-bios-promising-trials-and-strategic-outlook-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UPB"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":50,"code":"91000000","status":"200"}]}}